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S342 Poster Session IIsmall intestine, colon and liver. 94% of mice within the allogeneic
group had severe cGVHD as defined by a clinical score above 0.6
by 28 days. At sacrifice, after day 35 post adaptive transfer, total
thymocyte numbers in mice with severe cGVHD were more than
20-fold depleted compared to syngeneic controls. Furthermore,
the double positive thymocyte cell population (CD4+ CD8+) was
most markedly reduced. Within the single positive thymocyte cell
subsets, the CD4+ proportion was more significantly diminished
than the CD8+ subset, although both subsets were dramatically re-
duced in cGVHD mice compared to syngeneic controls. Similarly,
in the spleen, live splenocytes were 3-fold depleted in animals with
severe cGVHD compared to syngeneic controls. Both CD4+ and
CD8+ T cells were significantly reduced with the recent thymic
emigrant (RTE) CD4 proportion (CD4+ CD44lo CCR7+) most
severely affected. Within CD4+ splenocytes, the total number of
T regulatory cells (CD4hi CD127lo Foxp3+) was not significantly
different betweenmice with cGVHDandwithout; however, the pro-
portion of Treg in animals with cGVHDwas significantly increased.
These data show that severe cGVHD is associated with impaired
thymopoiesis, with relative CD4 lymphopenia and diminished
RTE numbers. Conversely, preliminary data show that improved
thymopoiesis is associated with less severe cGVHD.527
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In the setting of unmanipulated non myeloablative (RIC) hemato-
poietic stem cell transplantation (HSCT) the possibility of biologi-
cally significant donor Killer cell immunoglobulin-like receptors
(KIRs)/HLA-C genomic (KIR-ligand) mismatched is potentially
important. To define the role of KIRs and KIR-ligands polymor-
phism we retrospectively analyzed 37 patients who underwent to
HSCT from HLA identical siblings for myeloid (n 5 16) or lym-
phoid malignancy. Pateints and donor KIR genes and ligandspoly-
morphisms were determined by PCR_SSP (14 genes plus 2
pseudogenes) and analyzed with different transplantation endpoints.
15/37 (40%) pairs were heterozygote for C1/C2 groups to confirm
a polymorphisms in KIR genes also in a HLA-identical sibling set-
ting. 12/37 (32%) and 9/37 (24%)were homozygotes respectively
for C1 andC2 groups therefore lacking the KIR-ligandC1 for donor
inhibitory KIR2DL2/3 and 20 the KIR-ligand C2 for donor inhibi-
tory KIR2DL1. We cannot find any correlation with acute or
chronic GVHD and OS. On the contrary the absence of patients’
HLA-C ligand for the corresponding donor inhibitory KIR genes
was associated to a better disease free survival (DFS) (9 months ver-
sus 3 months, chi square 3,9; p 5 0,04 logrank test). Moreover the
absence in the recipient of groupC1 ligandwas associated to a higher
probability of CMV reactivation (chi square 4,14; p5 0,038). Finally
the presence in the donor of at least one KIR inhibitory receptor sig-
nificantly improved DFS (chi square 3,9; p 5 0,039), irrespective to
the presence of its HLA class I ligand in the recipient. Despite the
small cohort of patient our data suggest a significant impact of inhib-
itory KIR on disease progression/relapse. Further studies are ongo-
ing to assess the role of activating KIR genes and to evaluate the
impact on survival of KIR haplotype. If confirmed in larger series
and in unrelated setting, the assessment of KIR genotype may be
used in a more sophisticade donor selection.528
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Chronic graft-versus-host disease (cGvHD) is amajor cause of late
mortality related to allogeneic hematopoietic stem cell transplanta-
tion (HSCT). The difficulty in standardizing cGvHD diagnostic
criteria, classification and severity led the National Institute of
Health (NIH) to develop a consensus project to these criteria.
This proposal included the scores of involved sites and the overall
assessment of severity classified as none, mild, moderate or severe.
Validation of the NIH classification translated is the goal of a pro-
spective multicenter study conducted by the GvHD Study Group
Brazil-Seattle (GEDECH) in a cohort of patients with cGvHD
transplanted in Brazil. The purpose of the workshop held in
CEMO was to train physical examination, standardize diagnostic
criteria and improve the filling of the detailed forms of the protocol
by the participants.
Methods: Five HSCT centers included representatives and the pro-
gram encompassed practical assessment of the cases, training with
the physiotherapists and discussion of results. Nine patients, under
informed consent, agreed to be photographed before and be exam-
ined, in private rooms, by groups of three professionals at a time.
The groups were supervised by a dermatologist and an oral medicine
doctor. They had 20 minutes to evaluate each patient and fill the
forms. In the next step, the patients were submitted to physiotherapy
evaluation for strength and 2-minute walk tests. Finally, using the
summary of the cases, the images and forms, the coordinators dis-
cussed in plenary session, aspects and difficulties associated with
this methodology and protocol.
Results: Participants did not scored the percentage grade of each
type of lesion and agreed that 20 minutes per patient were inade-
quate. Themain issues raised at the meeting were: difficulty in estab-
lishing the percentage of erythema in movable and nonmovable
sclerosis; the need to describe the changes in each region or the
dominant aspect of the lesion; the definition of poikiloderma; the
relationship between scale A (gravity) and scale B scores (symptoms)
in the overall assessment of cGvHD; disagreement in understanding
the degree of restriction of oral intake and between the methodolo-
gies used in strength and walk tests.
Conclusion: The workshop clarified several doubts about the clini-
cal assessment of cGvHD and suggestions will be applied in extend-
ing the protocol to other centers in Brazil.529
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The use of cord blood permits allogeneic transplantation with
a high degree of HLA disparity, but a lower incidence of GVHD
than expected for the degree of mismatch. Nonetheless, the inci-
dence of grade II-IV acute GVHD (aGVHD) can be as high as
58%, and may be increased after double unit CBT. However,
GVHD after CBT may also be more responsive to corticosteroids
than that after allografts using adult donors. Therefore, we have in-
vestigated the treatment of grade II acute GI GVHD with single
agent budesonide (9mg daily) as first line therapy. We evaluated
the incidence, nature, and treatment response of grade II-IV
aGVHD in 101 double unit CBT recipients that were transplanted
between 10/01/05-05/30/10. Conditioning was myeloablative
(75%), or non-myeloablative (25%), and no patient received anti-
thymocyte globulin. GVHD prophylaxis consisted of a calcineurin
